GSK (GSK) is in advanced discussions to acquire privately-owned US biotech company IDRx for up to $1 billion, the Financial Times reported Wednesday, citing people close to the talks.
IDRx is developing a treatment for rare gastrointestinal tumors, according to the report.
GSK and IDRx didn't immediately respond to a request for comment from MT Newswires.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Price: 33.78, Change: -0.32, Percent Change: -0.92